A selection of interesting papers that were published in the month before our press date in major journals likely to report important results in gastroenterology and hepatology. Peter Hayes and John Plevris The Royal Inﬁrmary, Edinburgh EH3 9YW, UK Proton pump inhibitors are associated with Aliment Pharmacol Ther 2018; 47:246–258. doi: 10.1111/ accelerated development of cirrhosis, hepatic apt.14391. Epub 2017 Nov 3. decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C Durability of hepatitis B surface antigen seroclearance infection: results from ERCHIVES in untreated and nucleos(t)ide analogue-treated patients Li D.K., Yan P., Abou-Samra A.B., Chung R.T., Butt A.A. Yip T.C., Wong G.L., Wong V.W., Tse Y.K., Lui G.C., Background: Proton pump inhibitors are among the most Lam K.L., Chan H.L. commonly prescribed medications in the United States. Their safety in cirrhosis has recently been questioned, but Background & aims: It is uncertain if nucleos(t)ide ana- their overall effect on disease progression in noncirrhotic logue (NA)-induced hepatitis B surfaceantigen (HBsAg) patients with chronic liver disease remains unclear. seroclearance is durable. We investigated the impact of hepatitis B surface antibody (anti-HBs) and duration of Aim: To determine the impact of proton pump inhibitors consolidation antiviral therapy on the durability
European Journal of Gastroenterology & Hepatology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud